<- Go Home
Immuneering Corporation
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Market Cap
$295.7M
Volume
1.3M
Cash and Equivalents
$227.6M
EBITDA
-$63.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$10.08
52 Week Low
$1.10
Dividend
N/A
Price / Book Value
1.28
Price / Earnings
-2.61
Price / Tangible Book Value
1.32
Enterprise Value
$72.1M
Enterprise Value / EBITDA
-1.15
Operating Income
-$64.2M
Return on Equity
43.75%
Return on Assets
-25.91
Cash and Short Term Investments
$227.6M
Debt
$3.9M
Equity
$228.0M
Revenue
N/A
Unlevered FCF
-$27.7M
Sector
Biotechnology
Category
N/A